Teragnosis en medicina nuclear

  1. José Luis Carreras Delgado 1
  2. Alba M. Blanes García 2
  3. Cristina G. Wakfie-Corieh 2
  4. María N. Cabrera Martín 2
  5. Aída Ortega Candil 2
  6. Cristina Rodríguez Rey 2
  1. 1 Real Academia Nacional de Medicina de España – Medicina Física; Hospital Clínico San Carlos de Madrid
  2. 2 Hospital Clínico San Carlos de Madrid
    info

    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

Zeitschrift:
Anales de la Real Academia Nacional de Medicina

ISSN: 0034-0634

Datum der Publikation: 2020

Nummer: 137

Seiten: 54-59

Art: Artikel

DOI: 10.32440/AR.2020.137.01.REV06 DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: Anales de la Real Academia Nacional de Medicina

Zusammenfassung

Theranostics in Nuclear Medicine consists in using molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. This modality has undergone rapid development during the last decades, supporting “targeted therapy” and “personalized medicine” thanks to the research of a wide range of molecular targets. Theranostics has been used for years in thyroid cancer and hyperthyroidism and is currently being implemented in other entities such as neuroendocrine tumors and prostate cancer. In neuroendocrine tumors, ligands capable of binding to some somatostatin receptors are labeled with 68Ga are used for diagnostic use in the initial assessment of these patients and with 177Lu for destruction of tumor cells in metastatic and inoperable patients. The 177Lu also has a low proportion of γ emission that allows biodistribution to be confirmed by scintigraphy/SPECT. In prostate cancer, PSMA (membrane-specific prostate antigen) which is an overexpressed transmembrane glycoprotein in prostate tumors is used as a theranostic target. For diagnosis, 68Ga-PSMA-11 is used and 177Lu-PSMA-617 is used for treatment, which triggers selective cell death of prostate tumor cells, indicated in metastatic patients and in progression despite other treatments. As for the novel Fibroblast Activation Protein (FAP) expressed in different tumor entities, the ligand used is derived from quinoleins that have FAP inhibitory activity, known as Fibroblast Activation Protein Inhibitor (FAPI), present in the stroma of various malignant neoplasms. For diagnostic use in metastatic tumors, 68Ga-FAPI-04 is being used with rapid tumor distribution and excellent image contrast. Although there is little therapeutic evidence it is a promising radiopharmaceutical due to its easy combination with therapeutic radionuclides

Bibliographische Referenzen

  • Capdevila J, Hernando J, Perez‐Hoyos S, et al. Meta‐Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist. 2019;24(12):6–11.
  • Stueven AK, Kayser A, Wetz C, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: Past, present and future. Int J Mol Sci. 2019;20(12):3049-3062.
  • Van Binnebeek S, Vanbilloen B, Baete K, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol. 2016;26(3):900–909.
  • Ebbers SC, Braat AJAT, Moelker A, et al. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: Study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials. 2020;21(1):1–9.
  • Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(3):471–495.
  • García Garzón JR, de Arcocha Torres M, Delgado-Bolton R, et al. 68Ga-PSMA PET/CT in prostate cancer. Rev Esp Med Nucl Imagen Mol. 2018;37(2):130–138.
  • Barakat A, Yacoub B, Homsi M El, et al. Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer. Sci Rep. 2020;10(1):2705-2711.
  • Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–697.
  • Rauscher I, Düwel C, Haller B, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol. 2018;73(5):656–661.
  • Sachpekidis C, Eder M, Kopka K, et al. 68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(7):1288–1299.
  • Beheshti M, Manafi-Farid R, Geinitz H, et al. Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 135 cases. . J Nucl Med. 2020;jnumed.119.238071.
  • Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol [Internet]. 2019; Available from: https://doi.org/10.1016/j.eururo.2019.01.049
  • Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.
  • Yadav MP, Ballal S, Bal C, et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nucl Med. 2020;45(1):19–31.
  • Rasul S, Hacker M, Kretschmer-Chott E, et al. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47(3):713–720.
  • Rathke H, Giesel FL, Flechsig P, et al. Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq. J Nucl Med. 2018;59(3):459–465.
  • Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–463.
  • Jiang GM, Xu W, Du J, et al. The application of the fibroblast activation protein a-targeted immunotherapy strategy. Oncotarget. 2016;7(22):33472–33482.
  • Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736–1741.
  • Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154–158.
  • Zhang Y, Tang H, Cai J, et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett [Internet]. 2011;303(1):47–55. Available from: http://dx.doi.org/10.1016/j.canlet.2011.01.011
  • Ju MJ, Qiu SJ, Fan J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 2009;131(4):498–510.
  • Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423–1429.
  • Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–1422.
  • Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12(6):1193–1203.
  • Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–392.
  • Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol [Internet]. 2015;87:194–203. Available from: http://dx.doi.org/10.1016/j.yjmcc.2015.08.016
Fuente de los datos: Dialnet